I've started reading the Lilly study, because the initial study when I read it gave me great confidence that it would create little to no effect on RMD's business. This is a new study so will require more investigation.
Just on my initial read, had a chuckle at this bit.
This GLP1-s have some pretty nasty sides, and the above is only during the trial. You can only imagine the long term affects from long term use. Market being short term here again I think.
Why the drop?, page-24
-
- There are more pages in this discussion • 41 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$30.48 |
Change
-0.020(0.07%) |
Mkt cap ! $19.31B | |||
| Open | High | Low | Value | Volume |
| $30.48 | $30.61 | $30.35 | $42.73M | 1.403M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 21027 | $30.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $30.48 | 6882 | 3 |
View Market Depth
| Last trade - 16.10pm 16/07/2024 (20 minute delay) ? |
| RMD (ASX) Chart |